Your shopping cart is currently empty

Norathyriol is a potent PTP1B inhibitor with good cell permeability and oral availability.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $152 | In Stock | In Stock | |
| 5 mg | $373 | In Stock | In Stock | |
| 10 mg | $556 | In Stock | In Stock | |
| 25 mg | $896 | In Stock | In Stock | |
| 50 mg | $1,220 | In Stock | In Stock | |
| 100 mg | $1,650 | In Stock | In Stock | |
| 200 mg | $2,220 | In Stock | In Stock | |
| 1 mL x 10 mM (in DMSO) | $496 | In Stock | In Stock |
| Description | Norathyriol is a potent PTP1B inhibitor with good cell permeability and oral availability. |
| Targets&IC50 | PPARγ:153.5 μM (IC50), PPARβ:102.4 μM (IC50), PPARα:92.8 μM (IC50) |
| In vitro | Normal or IR L6 myotubes were incubated with Norathyriol (2.5 - 10 μM, 0.625 - 2.5 μM), mangiferin (10 - 40 μM, 2.5 - 10 μM) or rosiglitazone (20 μM) and/or 0.05 nM insulin for 24 h, respectively. The glucose consumption was assessed using the glucose oxidase method. Immunoblotting was performed to detect protein kinase B (PKB/Akt) and AMP-activated protein kinase (AMPK) phosphorylation in L6 myotubes cells. Norathyriol and mangiferin treatment alone increased the glucose consumption 61.9 and 56.3%, respectively, in L6 myotubes and made additional increasing with 0.05 nM insulin. In IR L6 myotubes, Norathyriol treatment made increasing with or without insulin, mangiferin treatment also made increasing but only when co-treated with insulin. Immunoblotting results showed that Norathyriol and mangiferin produced an increase of 1.9 - and 1.8-fold in the phosphorylation levels of the AMPK, but not in Akt[1] |
| Molecular Weight | 260.2 |
| Formula | C13H8O6 |
| Cas No. | 3542-72-1 |
| Smiles | Oc1cc(O)c2c(c1)oc1cc(O)c(O)cc1c2=O |
| Relative Density. | 1.766g/cm3 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 65 mg/mL (249.81 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (7.69 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.